Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination

Jaimie Z. Shing; Pamela C. Hull; Yuwei Zhu; Julia W. Gargano; Lauri E. Markowitz; Angela A. Cleveland; Manideepthi Pemmaraju; Ina U. Park; Erin Whitney; Edward F. Mitchel; Marie R. Griffin

doi:10.1016/j.pvr.2019.04.007

Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination

Jaimie Z. Shing, Pamela C. Hull, Yuwei Zhu, Julia W. Gargano, Lauri E. Markowitz, Angela A. Cleveland, Manideepthi Pemmaraju, Ina U. Park, Erin Whitney, Edward F. Mitchel, Marie R. Griffin

Behavioral Science

Research output: Contribution to journal › Article › peer-review

7 Citations (SciVal)

Abstract

Introduction: Evidence of human papillomavirus (HPV) vaccine impact on anogenital warts (AGWs) by race or urbanicity in the US is lacking. We evaluated HPV vaccine impact in Tennessee by assessing AGW trends among Tennessee Medicaid (TennCare) enrollees aged 15–39 years from 2006-2014. Methods: Persons with incident AGWs were identified using diagnosis/pharmacy codes from TennCare billing claims. We calculated sex-specific annual AGW incidence by age group, race, and urbanicity; estimated annual percent changes (APCs) using log-linear models; and performed pairwise comparisons by race and urbanicity. Results: AGW incidence decreased among females aged 15–19 (APC = −10.6; P < 0.01) and 20–24 years (APC = −3.9; P = 0.02). Overall trends were similar between Whites and Blacks, and between those living in metropolitan statistical areas (MSAs) and non-MSAs. Rates among males aged 15–19 years began decreasing after 2010. Among enrollees aged 25–39 years, rates increased or were stable. Conclusions: Following introduction of the HPV vaccine in 2006, AGWs decreased among age groups most likely to be vaccinated. The change in trend among young males after 2010 suggests early herd effects. Our findings indicate vaccine effects and support the importance of improving adherence to current vaccination recommendations for preventing AGWs and other HPV-related diseases.

Original language	English
Pages (from-to)	141-149
Number of pages	9
Journal	Papillomavirus Research
Volume	7
DOIs	https://doi.org/10.1016/j.pvr.2019.04.007
State	Published - Jun 2019

Bibliographical note

Funding Information:
This work was supported by the Emerging Infections Cooperative Agreement No. 5U01C10003 from the Centers for Disease Control and Prevention , and grant No. TL1TR002244 from the National Center for Advancing Translational Sciences , National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention nor the National Institutes of Health.

Funding Information:
This work was supported by the Emerging Infections Cooperative Agreement No. 5U01C10003 from the Centers for Disease Control and Prevention, and grant No. TL1TR002244 from the National Center for Advancing Translational Sciences, National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention nor the National Institutes of Health. The authors thank the Tennessee Division of TennCare of the Department of Finance and Administration for providing the data, and Dr. Alicia Beeghly-Fadiel, Vanderbilt University Medical Center, for providing careful review and helpful comments.

Publisher Copyright:
© 2019

Keywords

Anogenital warts
HPV vaccination
Impact
Trend

ASJC Scopus subject areas

Virology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pvr.2019.04.007

Cite this

Shing, J. Z., Hull, P. C., Zhu, Y., Gargano, J. W., Markowitz, L. E., Cleveland, A. A., Pemmaraju, M., Park, I. U., Whitney, E., Mitchel, E. F., & Griffin, M. R. (2019). Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination. Papillomavirus Research, 7, 141-149. https://doi.org/10.1016/j.pvr.2019.04.007

@article{8cf6cac641114250a274ae1474166178,

title = "Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination",

abstract = "Introduction: Evidence of human papillomavirus (HPV) vaccine impact on anogenital warts (AGWs) by race or urbanicity in the US is lacking. We evaluated HPV vaccine impact in Tennessee by assessing AGW trends among Tennessee Medicaid (TennCare) enrollees aged 15–39 years from 2006-2014. Methods: Persons with incident AGWs were identified using diagnosis/pharmacy codes from TennCare billing claims. We calculated sex-specific annual AGW incidence by age group, race, and urbanicity; estimated annual percent changes (APCs) using log-linear models; and performed pairwise comparisons by race and urbanicity. Results: AGW incidence decreased among females aged 15–19 (APC = −10.6; P < 0.01) and 20–24 years (APC = −3.9; P = 0.02). Overall trends were similar between Whites and Blacks, and between those living in metropolitan statistical areas (MSAs) and non-MSAs. Rates among males aged 15–19 years began decreasing after 2010. Among enrollees aged 25–39 years, rates increased or were stable. Conclusions: Following introduction of the HPV vaccine in 2006, AGWs decreased among age groups most likely to be vaccinated. The change in trend among young males after 2010 suggests early herd effects. Our findings indicate vaccine effects and support the importance of improving adherence to current vaccination recommendations for preventing AGWs and other HPV-related diseases.",

keywords = "Anogenital warts, HPV vaccination, Impact, Trend",

author = "Shing, {Jaimie Z.} and Hull, {Pamela C.} and Yuwei Zhu and Gargano, {Julia W.} and Markowitz, {Lauri E.} and Cleveland, {Angela A.} and Manideepthi Pemmaraju and Park, {Ina U.} and Erin Whitney and Mitchel, {Edward F.} and Griffin, {Marie R.}",

note = "Funding Information: This work was supported by the Emerging Infections Cooperative Agreement No. 5U01C10003 from the Centers for Disease Control and Prevention , and grant No. TL1TR002244 from the National Center for Advancing Translational Sciences , National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention nor the National Institutes of Health. Funding Information: This work was supported by the Emerging Infections Cooperative Agreement No. 5U01C10003 from the Centers for Disease Control and Prevention, and grant No. TL1TR002244 from the National Center for Advancing Translational Sciences, National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention nor the National Institutes of Health. The authors thank the Tennessee Division of TennCare of the Department of Finance and Administration for providing the data, and Dr. Alicia Beeghly-Fadiel, Vanderbilt University Medical Center, for providing careful review and helpful comments. Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = jun,

doi = "10.1016/j.pvr.2019.04.007",

language = "English",

volume = "7",

pages = "141--149",

}

TY - JOUR

T1 - Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014

T2 - The impact of human papillomavirus vaccination

AU - Shing, Jaimie Z.

AU - Hull, Pamela C.

AU - Zhu, Yuwei

AU - Gargano, Julia W.

AU - Markowitz, Lauri E.

AU - Cleveland, Angela A.

AU - Pemmaraju, Manideepthi

AU - Park, Ina U.

AU - Whitney, Erin

AU - Mitchel, Edward F.

AU - Griffin, Marie R.

N1 - Funding Information: This work was supported by the Emerging Infections Cooperative Agreement No. 5U01C10003 from the Centers for Disease Control and Prevention , and grant No. TL1TR002244 from the National Center for Advancing Translational Sciences , National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention nor the National Institutes of Health. Funding Information: This work was supported by the Emerging Infections Cooperative Agreement No. 5U01C10003 from the Centers for Disease Control and Prevention, and grant No. TL1TR002244 from the National Center for Advancing Translational Sciences, National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention nor the National Institutes of Health. The authors thank the Tennessee Division of TennCare of the Department of Finance and Administration for providing the data, and Dr. Alicia Beeghly-Fadiel, Vanderbilt University Medical Center, for providing careful review and helpful comments. Publisher Copyright: © 2019

PY - 2019/6

Y1 - 2019/6

N2 - Introduction: Evidence of human papillomavirus (HPV) vaccine impact on anogenital warts (AGWs) by race or urbanicity in the US is lacking. We evaluated HPV vaccine impact in Tennessee by assessing AGW trends among Tennessee Medicaid (TennCare) enrollees aged 15–39 years from 2006-2014. Methods: Persons with incident AGWs were identified using diagnosis/pharmacy codes from TennCare billing claims. We calculated sex-specific annual AGW incidence by age group, race, and urbanicity; estimated annual percent changes (APCs) using log-linear models; and performed pairwise comparisons by race and urbanicity. Results: AGW incidence decreased among females aged 15–19 (APC = −10.6; P < 0.01) and 20–24 years (APC = −3.9; P = 0.02). Overall trends were similar between Whites and Blacks, and between those living in metropolitan statistical areas (MSAs) and non-MSAs. Rates among males aged 15–19 years began decreasing after 2010. Among enrollees aged 25–39 years, rates increased or were stable. Conclusions: Following introduction of the HPV vaccine in 2006, AGWs decreased among age groups most likely to be vaccinated. The change in trend among young males after 2010 suggests early herd effects. Our findings indicate vaccine effects and support the importance of improving adherence to current vaccination recommendations for preventing AGWs and other HPV-related diseases.

AB - Introduction: Evidence of human papillomavirus (HPV) vaccine impact on anogenital warts (AGWs) by race or urbanicity in the US is lacking. We evaluated HPV vaccine impact in Tennessee by assessing AGW trends among Tennessee Medicaid (TennCare) enrollees aged 15–39 years from 2006-2014. Methods: Persons with incident AGWs were identified using diagnosis/pharmacy codes from TennCare billing claims. We calculated sex-specific annual AGW incidence by age group, race, and urbanicity; estimated annual percent changes (APCs) using log-linear models; and performed pairwise comparisons by race and urbanicity. Results: AGW incidence decreased among females aged 15–19 (APC = −10.6; P < 0.01) and 20–24 years (APC = −3.9; P = 0.02). Overall trends were similar between Whites and Blacks, and between those living in metropolitan statistical areas (MSAs) and non-MSAs. Rates among males aged 15–19 years began decreasing after 2010. Among enrollees aged 25–39 years, rates increased or were stable. Conclusions: Following introduction of the HPV vaccine in 2006, AGWs decreased among age groups most likely to be vaccinated. The change in trend among young males after 2010 suggests early herd effects. Our findings indicate vaccine effects and support the importance of improving adherence to current vaccination recommendations for preventing AGWs and other HPV-related diseases.

KW - Anogenital warts

KW - HPV vaccination

KW - Impact

KW - Trend

UR - http://www.scopus.com/inward/record.url?scp=85064315725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064315725&partnerID=8YFLogxK

U2 - 10.1016/j.pvr.2019.04.007

DO - 10.1016/j.pvr.2019.04.007

M3 - Article

C2 - 30980966

AN - SCOPUS:85064315725

VL - 7

SP - 141

EP - 149

ER -

Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this